David Amsellem
Stock Analyst at Piper Sandler
(4.22)
# 356
Out of 4,778 analysts
144
Total ratings
54.1%
Success rate
11.91%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $28.40 | +12.68% | 8 | Mar 21, 2025 | |
| OPTN OptiNose | Downgrades: Neutral | $15 → $9 | $9.17 | -1.85% | 3 | Mar 21, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $5.86 | -31.74% | 5 | Mar 7, 2025 | |
| INDV Indivior | Maintains: Overweight | $16 → $13 | $9.58 | +35.70% | 5 | Mar 6, 2025 | |
| VTRS Viatris | Reiterates: Neutral | $14 → $10 | $8.95 | +11.79% | 7 | Mar 5, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $67 → $78 | $58.28 | +33.84% | 6 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $163 → $176 | $135.20 | +30.18% | 13 | Feb 26, 2025 | |
| AMGN Amgen | Maintains: Overweight | $310 → $329 | $306.76 | +7.25% | 2 | Feb 10, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Neutral | $37 → $36 | $30.13 | +19.48% | 7 | Feb 4, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $23 → $30 | $15.69 | +91.20% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $107 → $132 | $131.71 | +0.22% | 1 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $8.18 | +58.92% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $9 | $8.53 | +5.51% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $116.14 | +37.77% | 9 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $8.53 | +29.03% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $33.89 | +9.18% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $66.40 | +2.41% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $33.04 | +8.96% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.00 | -57.14% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $24.56 | +71.01% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $14.72 | +63.04% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.23 | +209.60% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.51 | +1,295.35% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $120.45 | -6.19% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $144 → $12 | $5.62 | +113.52% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $32.99 | +27.31% | 3 | Oct 16, 2023 |
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $28.40
Upside: +12.68%
OptiNose
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.17
Upside: -1.85%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $5.86
Upside: -31.74%
Indivior
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $9.58
Upside: +35.70%
Viatris
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $8.95
Upside: +11.79%
Corcept Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $67 → $78
Current: $58.28
Upside: +33.84%
Jazz Pharmaceuticals
Feb 26, 2025
Reiterates: Overweight
Price Target: $163 → $176
Current: $135.20
Upside: +30.18%
Amgen
Feb 10, 2025
Maintains: Overweight
Price Target: $310 → $329
Current: $306.76
Upside: +7.25%
Collegium Pharmaceutical
Feb 4, 2025
Maintains: Neutral
Price Target: $37 → $36
Current: $30.13
Upside: +19.48%
Teva Pharmaceutical Industries
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $15.69
Upside: +91.20%
Jan 14, 2025
Downgrades: Neutral
Price Target: $107 → $132
Current: $131.71
Upside: +0.22%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $8.18
Upside: +58.92%
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $8.53
Upside: +5.51%
Dec 23, 2024
Reiterates: Overweight
Price Target: $160
Current: $116.14
Upside: +37.77%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.53
Upside: +29.03%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $33.89
Upside: +9.18%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $66.40
Upside: +2.41%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $33.04
Upside: +8.96%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.00
Upside: -57.14%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $24.56
Upside: +71.01%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $14.72
Upside: +63.04%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.23
Upside: +209.60%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.51
Upside: +1,295.35%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $120.45
Upside: -6.19%
Nov 14, 2023
Downgrades: Neutral
Price Target: $144 → $12
Current: $5.62
Upside: +113.52%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $32.99
Upside: +27.31%